|
Cysteine-Methylene-Carbamoyl-1,10-Phenanthroline
|
DB04437 |
|
|
scyllo-inositol
|
DB03106 |
[An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction. Scyllitol has been investigated for the treatment of Alzheimer Disease.] |
|
Beta-Alanine
|
DB03107 |
[An amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported. [PubChem]] |
|
Brivudine monophosphate
|
DB04438 |
|
|
Alkaline Phosphatase
|
DB05768 |
[Alkaline Phosphatase (AP) is an oral treatment and has a very
favorable side-effect profile. AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.] |
|
Andrographolide
|
DB05767 |
[HMPL-004 is a botanical product extracted from a herb that occurs naturally in China. The herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases.] |
|
2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
|
DB03104 |
|
|
5-Hydroxy Norvaline
|
DB03105 |
|
|
3-Fluoro-L-tyrosine
|
DB04436 |
[3-Fluoro-L-tyrosine is a solid. This compound belongs to the phenylpropanoic acids. These are compounds whose structure contain a benzene ring conjugated to a propanoic acid. 3-Fluoro-L-tyrosine targets the protein superoxide dismutase [mn], mitochondrial.] |
|
ACP-104
|
DB05766 |
[ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.] |
|
ATX-201
|
DB05765 |
[ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their expected primary and exploratory objectives.] |
|
Verpacamide A
|
DB04433 |
|
|
2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
|
DB03102 |
|
|
Thymidine-5'- Diphosphate
|
DB03103 |
|
|
Naphthyridine Inhibitor
|
DB04434 |
|
|
4-epi-vancosaminyl derivative of vancomycin
|
DB04431 |
|
|
6-Nitroindazole
|
DB03100 |
|
|
Ribose-1-Phosphate
|
DB03101 |
|
|
ZK-805623
|
DB04432 |
|
|
Nebularine
|
DB04440 |
|
